STM JOURNALS

Recent Trends in
Infectious Diseases

Volume 1, Issue 2, 2024
July-December
DOI (Journals): 10.37591/RTID

https://journals.stmjournals.com/rtid

Review RTID

Risk and Opportunities in Development of New Drugs: A New Perspective

Shubham Kumar[1,*], Sweta Ravindra Singh[2]

Abstract

The procedures of drug discovery and development are briefly described in this article. Our mission is to support researchers whose work may have an impact on the discovery and/or development of new drugs by helping them structure research reports so that findings are properly placed in the drug discovery and development process and successfully translate preclinical research into human subjects .One overarching theme of our article is the length, complexity, and expense of the process, which forces the consideration of numerous biological targets for every new drug that is eventually approved for clinical use as well as the potential need for new research tools to examine each new target. The efficacy of the development process can be increased by studies that help to resolve any of the numerous scientific and practical problems that are involved in it. By being aware of these problems, actions can be taken early to improve chances of success. Drug Regulatory Affairs refers to all facets of the pharmaceutical process of drug discovery and research, which also addresses numerous risks and opportunities of drug development, and which are subject to varying degrees of regulations of various nations, including India, the United States, and Europe. The pharmaceutical law framework is employed as guidelines on Quality, Safety, and Efficacy of a Drug as well as Health Authorities' Attitudes and Requirements are Employed for the Correct Pathway of Pharmaceutical Needs and Have A Great Influence On The Drug Development Process And Had Success Through It. Professionals in regulatory affairs interact with each of these elements in order to achieve the intended outcome of drug development. The health authorities are designed to direct and analyses the medication that satisfies the required standards for quality and efficacy.

Keywords: pharmacology, drug discovery , opportunities, patient health , natural resources

INTRODUCTION

In the 19th century, life sciences made significant strides, particularly in the fields of chemistry, physiology, and pharmacology, which established the groundwork for current medication creation and research. This is when the regulation of medicines began. Research institutions are heavily involved in the creation of novel drugs, which presents both a risk and an opportunity to enhance patient health [1]. Many pharmaceutical businesses face a significant issue when deciding which new medications to develop since there are too many chances but not enough resources. Project prioritization and new product portfolio selection have traditionally been the purview of the corporation's new product armor division. Following a number of procedures, including regulatory ethics review by a specific organization and clinical studies, the new drug is put on the market. Drug Regulatory Affairs refers to all facets

***Author for Correspondence**
Shubham Kumar
E-mail: shubham.2024bph1067@kiet.edu

[1]KIET School of Pharmacy, KIET Group of Institutions, Delhi - Meerut Road, NH-58, Ghaziabad, Uttar Pradesh, India

Received Date: December 08, 2023
Accepted Date: December 18, 2023
Published Date: December 30 , 2023

Citation: Shubham Kumar, Sweta Ravindra Singh. Risk and Opportunities in Development of New Drugs: A New Perspective. Recent Trends in Infectious Diseases. 2024; 1(2): 19–28p.

© STM Journals 2024. All Rights Reserved

of the pharmaceutical process surrounding drug discovery and research that also deal with numerous risks and opportunities associated with drug development and are subject to varying degrees of regulations from nations like India, the United States, and Europe [2]. Additionally, the majority of neglected diseases, including cutaneous leishmaniasis, have not yet been treated with drugs as a result of this new strategy. An efficient and long-lasting solution is to increase the ability of nations where these diseases are common to discover new medical treatments and to enable the exploration of previously untapped natural resources.

THE PROCESS OF DRUG DEVELOPMENT

Drug development has become increasingly complex over the past 40 years, requiring the completion of preclinical studies, investigational new drug (IND) submissions, and clinical trials before FDA approval of Biologics for marketing license applications (BLAs) and new drug applications (NDAs) that are routinely reviewed prior to licensing.

Following approval, drug performance is then once again submitted to regulatory bodies for post-marketing research. After a complete medical review, the main objective is to provide patients with safer, more effective treatments as soon as is practical [3]. Drug development is the process of bringing a new drug "from the bench to the bedside."A drug's conception, creation, and patient use approval can take 10 to 15 years. In some instances, the procedure for developing and approving drugs can be expected for example, If the medication offers the first treatment option for a condition or demonstrates a significant advantage over current medications [4]. The development of a new drug from target selection to commercial approval takes more than 12 years, and often much longer, according to studies in all therapeutic groups [5 To create a new drug modifies the pathogenesis of AD we should expect more biological targets to use gene therapy strategies It will require research and study.

THERE ARE SOME PHASES IN THE DEVELOPMENT OF NEW DRUGS

Phase 1 – Discovery of New Drugs

There are a few specific benefits associated with using botanical sources as the foundation for drug development programs: Choosing a candidate species for research can typically be done based on how long humans have used it. This approach is based on the assumption that the recognized active ingredients in these plants are safer than plant species that have never been used by humans.One may try to create an active molecule at a later time to ease pressure on the resource. This type of methodology was previously used in the drug development of Rauwolfia serpentina, Digitalis purpurea, etc. [6]. The majority of drugs have historically been found either through the accidental or deliberate identification of the active component in traditional treatments.

Another approach is to understand the molecular physiological mechanisms that regulate disease and infection, and then target specific factors according to this understanding.A preclinical drug discovery program's objective is to produce one or more clinical candidate molecules that each have enough proof of biologic activity at a disease-relevant target, as well as enough safety and drug-like properties, to be put through human testing. Most drug discovery systems require the development of multiple candidate molecules due to concerns about safety, acoustics, potency, intellectual property protection, or other variables Modern drug discovery systems almost always require that there is extensive collaboration in chemistry, biology, toxicology, and biochemistry. However, small-molecule drug screening programs typically generate more information through more efficient analytical methods that evaluate multiple analytes in multiple assays[7].

Phase 2: New Drug Development

© STM Journals 2024. All Rights Reserved

Typically, the first step in developing a new drug is to identify a biological target (e.g., receptor, enzyme, protein, gene, etc.) that affects a biological process that is thought to be dysfunctional in patients with a condition such as Alzheimer's disease (AD) [8] . The process of discovering new drugs is expensive because R&D and clinical trials are expensive.A single new drug molecule must be developed for nearly 12 to 15 years from the time it is discovered until it is sold to patients. Each effective drug will likely cost between $900 million and $2 billion in research and development costs on average. This money covers the cost of thousands of failed attempts: only one in 5,000–10,000 drugs is finally approved [9]. Prior to reaching the pharmacy shelf, a new drug will typically take 10 to 15 years and cost more than $2 billion. Natural resources used to be a major source of new synthetic compounds in drug discovery, before the move toward higher synthesis and development based on synthesis.

The price and duration of early drug discovery are being drastically cut, but they are largely unaffected by new technologies like ultra-high-throughput drug screening and artificial intelligence. Is there any alternative, perhaps quicker and less expensive, methods for finding new drugs? Is drug repurposing an effective substitute? In this overview, we go over various methods of drug discovery and their advantages and disadvantages[10].

The Stages of Developing a Drug

Early drug discovery

There is an important "step" in the discovery of new drugs. Academic and technological scientists work together to identify potential drug targets for a disease in order to identify new drugs that can act on specific target organisms affecting the disease.The goal is to treat the disease. Animal models and in vitro research are used in this stage's work in laboratories [4].

Target Identification and Validation

Knowing all the clinical stages of the disease and the precise role of the target in that context is one of the most important aspects of developing "good" treatments. Examples of such compounds include small molecules and biopharmaceuticals. The search for "good" pharmaceutical targets can be performed using "practical" methods such as target inversion and target detection. Drug targets with "universal" utility are considered "good" targets. They can also be found through publicly available databases and published scientific literature. Before launching an analytics campaign intended to identify a "hit," make sure the goal is validated [4].

Preclinical research

Preclinical development refers to the processes that occur between the initiation of a human clinical trial and the discovery of a drug in the laboratory. Preclinical research aims to conduct randomized clinical trials through various methods such as optimal drug selection, routes of administration, frequency of administration, and length of time, identify the first candidates to choose from hits, and how best to scale for -New products to help manufacturing.Each preclinical development package can have unique details, but they all share some basic components. To define the pharmacokinetic profile, assess general safety, and spot toxicity patterns, mammalian models that are rodent- and non-rodent-based are used. One or more species can be used to estimate the residence time of a drug in the body, based on its intestinal absorption, distribution, metabolism and excretion characteristics Toxicity and safety assessment appropriate defines therapeutic indications and identifies potential target organs for adverse effects, which are used to select initial starting doses for clinical trials[11].

Investigational new drug application

© STM Journals 2024. All Rights Reserved

An investigational new drug application (IND) is a request for Food and Drug Administration (FDA) approval to administer an investigational drug or biologic (serum, vaccines, antitoxin, antigen, etc.) to humans No, they must be consumed first obtain such patents Most INDs are filed by creators (usually sponsors) and pharmaceutical experts. In some cases, individuals can fund their own research. It should be easy for commercial manufacturers to decide whether to file an IND.

On the other hand, it can be challenging for the health professional to determine whether the study they are planning (a) requires an IND, (b) is medically, pharmaceutically, or professionally related (c) can be managed by internal committees [12].

It is morally imperative to develop drugs to treat the wide range of human diseases and disorders but testing novel medications on human test subjects is fraught with potential ethical problems. What is the best way to reconcile support for individual rights with general interest?Medical experiments on humans must be properly justified and closely regulated, and this is the responsibility of international regulatory bodies of government. We concentrate on the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in this article, as well as the process for using novel investigational products to treat humans legally [13].

Phase 3 – FDA Drug Review

Paradoxical objectives are involved in the regulation of medical device and pharmaceutical development, production, marketing, and sales. It must make sure that new and efficient medical treatments are quickly available to the public while also safeguarding against harmful therapies and predatory marketing techniques that mislead patients about unproven treatments. In the U.S. these regulatory responsibilities are vested in the Food and Drug Administration (FDA) [14] . Currently, the drug must pass preclinical testing, rigorous human clinical trials, and post-test FDA regulatory approval before it can move from early indication to potential treatment the promise of hitting a molecule.This procedure for drugs can take ten to fifteen years and cost millions of dollars [15]. Comparing the regulatory process for drugs to the pathways for approval of medical devices, the latter is typically quicker and less expensive. Medical device development takes, on average, 3 to 7 years from concept to market, while drug development typically takes 12 years [16]. The advancement and extension of human life have been greatly aided by modern medicine and science. Nevertheless, there are still many diseases and conditions without adequate treatmentsPublished in September 2012 by the President's Council on Science and Technology (PCAST) under the title "Stimulating Innovation in Drug Discovery, Development, and Evaluation.". It found that only 350 therapies have received approval to treat the 7,000 rare diseases that affect about 30 million Americans [17].

If the FDA rules that the product is safe and effective for its intended purpose, it is important to work with the manufacturer. We call this labeling. Conditions for approval are clearly defined on the product label and instructions for use are provided. However, problems still need to be resolved before the medicine can be licensed for marketing. In other situations, the FDA needs more research. The developer now has the option of continuing or stopping further development. There are resources for formal appeal if a developer disagrees with an FDA decision [18].

Phase 4 –FDA Post-Market Drug Safety Monitoring

Phase IV trials are conducted after FDA approval of the drug or device. These studies are also acknowledged as post-approval monitoring that includes pharmacovigilance and ongoing technical assistance. Phase 4 trials use a variety of observational methods and research models to assess the safety, cost-effectiveness, and effectiveness of interventions in real-world settings) can be implemented. Consequently, the months and even years that extend the shelf life of a commercial product are important in providing a true picture of its safety. FDA evaluates complaints of problems with

© STM Journals 2024. All Rights Reserved

prescription and over-the-counter medications and may decide to add warnings to dosing instructions or other practice advice, as well as other events for more severe adverse drug reactions. Passive surveillance (voluntary reporting) or the gathering of spontaneously reported adverse events from healthcare professionals and consumers after the administration of a pharmaceutical product have traditionally been used to monitor product safety. With the advancement of computers and electronic medical records, it is now possible to conduct active surveillance (a proactive search) of adverse events, in which biopharmaceutical companies and regulatory organizations can search vast databases of healthcare records to identify adverse events related to the use of a medicinal product. Although each system has pros and cons, when used in tandem, they offer a moderately effective method of product safety monitoring [19]. Post-marketing surveillance (PMS), in its simplest form, is the process of keeping an eye on a drug's safety after it is approved for sale by a regulatory body and has successfully completed clinical trials. Finding both positive and negative effects that had not yet been recognized is the main goal of the PMS. Using drugs off-label, having problems with orphan drugs, and having issues with conducting international clinical trials in children are all important factors that can be considered [20]. Post-marketing cohort studies to find unidentified ADRs have been deemed unsuccessful. The best method for identifying rare adverse events that happen concurrently with drug use is likely to continue to be spontaneous reports. The purpose of post-marketing cohort studies may be to clarify adverse events that happen more frequently in drug-exposed people than in the general population despite being relatively common in both populations. Compared to spontaneous reports, epidemiologic cohort studies enable a greater degree of risk factor assessment and confounding control. A rich data source of disease risk factors is provided by large cohorts that were not created specifically to detect ADR. At low marginal cost, ADR surveillance can be added. Researchers have examined oral ulcers and the use of non-steroidal anti-inflammatory drugs using epidemiologic cohort studies to examine risk factors for breast cancer from postmenopausal hormone use [21].

Risk in Development of New Drugs

Choosing which new products to develop is one of the biggest problems the pharmaceutical industry is facing. The problem of investment decision and product development was looked at in this study. An investigation was conducted into a fictitious case of a company called Healthcare Company investing in new products for either Product A or Product B. The new product development strategies were investigated using the NPV framework, as it had been in earlier empirical studies. In order to examine the dominant strategy in more detail, the stochastic dominance methodology was also used. This study looked at two different investment scenarios: one where each product received 100% of the funding and another where each drug received an equal amount. The findings indicated that the healthcare provider should only spend money on one of the pharmaceuticals. Consistent results were obtained using every method used in this study [22]. According to current estimates, it currently costs around $70,000,000 to develop a new drug in the United States, and the process typically takes 8 years from discovery to FDA approval. Even though the rate is rising, only one out of every ten novel chemical entities first observed in humans will ever be turned into a product. The others will fail for a number of reasons, mostly because of their toxicity, lack of effectiveness, or inability to outperform rival products. A company's willingness to invest in the quite risky development of a new drug is typically based on a parent, who shields the product from competition for 17 years in the United States and for variable but similar durations in other countries [23]. Because failing to understand the business perspective could result in the unmet demand for medical care, medical companies and other stakeholder groups have been looking into ways to improve the efficiency of drug development [24].

Numerous factors could contribute to failure, including the wrong choice of objective, an inability to identify appropriate compounds in the presence of unexpected toxicity, and a lack of efficacy in clinical trials.

There are many scientific reasons to discontinue drug development, including:

- Routine policy changeover in medical industry,

© STM Journals 2024. All Rights Reserved

- Changeover in medicine rules and regulation,
- Conditions for regulatory approval,
- Successful competitor or fragile cognitive possessions.
- Medicines that the constitutional domination approved created a failing economy.

The new project's scientific components, as well as the previously mentioned plan, legal issues, and business problems, all carry some risk.

TYPES OF RISK FACTORS

In account of drug development, two major types of risks can be distinguished below:

1. Technical risks
2. Translational risks.

Technical Risks

Technical risks are those that result from being unable to identify and sufficiently characterize the proper compound that runs into the required framework to designate chosen aim.

Technical risks will come under the following on,

- The absence of appropriate assays,
- Unable to produce suitable materials or bioreagents,
- Lack of selectivity toward the target,
- Unsuitable pharmacokinetics,
- Toxicity of the developed molecules.

Translational Risks

Translational risk refers to individuals who are accountable for compounds with an alternative rational ideal profile having unsuitable clinical efficacy. This lack of efficacy may be caused by the wrong goal being chosen, the use of a planned structure that is not diagnosing human ailment, or the failure of the particle to capture the goal under clinical conditions.

The following are the outcomes of translating translational risks into drug development:

- Goal hypotheses rely on incorrect qualification.
- Absence on the outgrowth connection: unnecessary passage, counter regulation in suppression or elimination.
- Inadequate knowledge of biology and infection's pathophysiological process.
- A pre-diagnosis framework was suggested that took diagnosis circumstances into account.
- Insufficient anthropoid evidence.
- There are no biological markers to describe therapy adherence or success.
- Inability to identify the proper sick patient for treatment.
- Not a supplement to the current therapy.

There is a growing consensus that conventional strategies for reducing costs and boosting productivity have basically reached their limits as the pharmaceutical industry strives to revolutionize drug development. To manage the three main sources of risk that currently interact to drive up the cost of drug development, companies can use their assets more efficiently with the aid of a variety of innovative business tools and platforms. Which are:

- Portfolio risk is the hazard associated with accurately estimating the clinical utility and worth of a candidate drug.
- Operational risk refers to the logistical and management difficulties associated with getting timely access to reliable clinical data about a candidate drug from the appropriate sources.
- Asset risk Exposures resulting from inconsistencies between the operations' fixed cost base and the demand for delivering clinical data that is pertinent and useful to regulatory decision-makers.

© STM Journals 2024. All Rights Reserved

MANAGEMENT OF RISKS IN DEVELOPMENT OF NEW DRUGS

The search for new drugs is risk management. Starting a new project for drug discovery can mark the beginning of a journey that could last more than 12 years and cost more than several hundred million euros. However, fewer than 1% of all drug research initiatives will yield a successful product. As a result, the majority of funds allocated to pharmaceutical research and development will eventually not go toward the few molecules that succeed in reaching the market, but rather toward the numerous molecules and initiatives that fall short of their goals. Failure can have a variety of causes, such as choosing the incorrect target, having trouble finding suitable lead compounds, unexpected toxicity, or ineffectiveness in clinical trials. Projects can also be abandoned for non-scientific reasons, such as persistent strategy changes in the pharmaceutical industry, modifications to drug legislation or the requirements for regulatory approval, the success of a rival company, or inadequate intellectual property. And even drugs that have received regulatory authority approval may not be profitable. They simply won't provide a sufficient return on the initial investment to support additional R&D due to cost containment measures in the healthcare systems of many different countries [24]. One of the most crucial tools in new drug applications to evaluate the risk of a drug product (i.e., physical harm and/or harm to the user's health) is risk management. Through improved productivity and knowledge sharing, risk management fosters quality and has a significant potential to lessen the amount of catch-up work required to mitigate the effects of subpar quality (such as non-conformance, deviations/investigations, corrections, rework, scrap, complaints, etc.). By focusing on the critical things rather than wasting time and money on low-risk tasks, risk management helps to offer justification.

The ability to use risk management to identify and support process improvements is very advantageous. Additionally, risk assessments can help pharmaceutical companies identify flaws and develop data- and science-based justifications. The risk management process is a continuous process that necessitates documentation during the product life cycle and design development (Figure 1). Risk management is a procedure with clearly defined steps that, when followed in order, support the intended product qualityRisk assessment tools may also be used to validate the processes (e.g., CFR 21, Part 820, Quality Management Regulations, the methodology set forth in the FDA Code of Federal Regulations). [25].

© STM Journals 2024. All Rights Reserved

The risk management process includes the following elements: risk assessment and analysis -risk management -development and remediation follow-up.



Figure 1. Drug total product of life cycle.

OPPORTUNITIES IN DEVELOPMENT OF NEW DRUG

Drug development is faced with the dual challenges of rising costs and mounting pricing pressure. Pharmaceutical companies and numerous other stakeholders are debating how to boost the effectiveness of drug R&D to prevent that a perceived lack of a commercial perspective would leave existing medical requirements unmet. Based on an international conference held in January 2016 and organized by the Medical School of the University of Duisburg-Essen (Germany), we examine the potential and challenges of three specific areas, namely public-private partnerships, adaptive designs, and big data. Public-private partnerships can take on a variety of shapes in terms of their size, duration, member's types, and scope. They range from small, multi-party consortia to big, project-specific collaborations. Each of them has unique chances and contends with unique difficulties. Investigator-initiated studies, one of the common forms of partnership, have a number of financial, ethical, and legal repercussions. Adaptive trial designs are also being considered more and more. Adaptive, however, should not be confused with the repurposing of a failed experiment; this requires thorough planning and specification before a trial even begins. The opposite of adaptive trial design may be adaptive licensing. Another chance to transform information already in existence into knowledge that can be used for drug research and development is through the use of big dataOne of the many issues with big data processing is confidentiality and navigating informed consent restrictions.Speakers and attendees at the conference were persuaded that the proper application of the aforementioned novel choices could in fact aid to improve the efficacy of next medication development [26]. The necessity for treating diseases with high priority in poor nations has not been met by the present paradigm for drug research. One such illness, cutaneous leishmaniasis, has seen hardly any new, efficient medications created in the previous 70 years. Through the establishment of Priority Review Vouchers (PRVs) and Product Development Partnerships, pharmaceutical businesses have been encouraged to focus more on neglected diseases over the past 20 years (PDPs). However, research institutions and the pharmaceutical industry in wealthy nations receive the lion's share of the funding provided for R&D by PRVs and PDPs. Additionally, the majority of neglected diseases, including cutaneous leishmaniasis, have not yet been treated with medications as a result of this new strategy. An efficient and long-lasting solution is to

© STM Journals 2024. All Rights Reserved

increase the capacity for medical research in nations where these diseases are common and to enable the exploration of previously untapped natural resources [27].

Some opportunities in Development of new drugs are:

- The process of developing a drug is time-consuming, expensive, and fraught with uncertainty as to whether the drug will be successful.
- Target identification is difficult because the pathophysiology of many nervous system disorders is unknown.
- Animal models frequently fail to fully reproduce a disorder or disease.
- More clinical phenotyping and end typing may be able to address issues with patient population heterogeneity.
- A greater focus on human data may result in more accurate target detection and validation.
- Insufficient diagnostic and therapeutic biomarkers have been validated to formally identify and quantify biological states.
- Pre-IND meetings can help clear up confusion about the current regulatory procedures for investigational new drug (IND) applications [28].

CONCLUSION

Numerous risks and benefits are connected to the development of new drugs. But reducing the risk through new methods and laws will assist the pharmaceutical industry in conducting research and developing new drugs. For a population that is expanding, this will improve patient quality of life. They believed that the fundamentals for developing new medications will be organized simultaneously for all medications, demonstrating the proper structure for releasing new medications into trade in a timely manner with sustainable care. Therefore, it is economically very important for the development of new drugs to manage fundamental activities properly.

REFERENCES

1. Munro D. SAS and GSK Pull Big Pharma into Big Data Collaboration.
2. Rajashekar S, Abimanyu S. Risk and Opportunities in Development of New Drug. Research Journal of Pharmacy and Technology. 2020;13(6):3041-4.
3. Senthil T, Selvaraj V, Jawahar N, Venkatachalam S. An Overview of Indian Veterinary Medicine Regulation. International Journal of Pharmaceutical Research (09752366). 2020 Jul 2.
4. Wang Z, Yang B. General Process for Rational Design and Discovery of MTDs. InPolypharmacology: Principles and Methodologies 2022 Aug 2 (pp. 661-676). Cham: Springer International Publishing.
5. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics. 2010 Mar;87(3):272-7.
6. Katiyar C, Gupta A, Kanjilal S, Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu. 2012 Jan;33(1):10.
7. Drews J. Drug discovery: a historical perspective. science. 2000 Mar 17;287(5460):1960-4.
8. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017 Nov 1;3(4):651-7.
9. An overview of new drug discovery and development. (n.d.). PharmaTutor. Retrieved January 2, 2022, from https://www.pharmatutor.org/articles/an-overview-of-new-drug-discovery-and-development
10. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future medicinal chemistry. 2020 Feb;12(10):939-47.
11. Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC neurology. 2009 Jun;9(1):1-3.

© STM Journals 2024. All Rights Reserved

12. Levine G, Abel N. Investigational new drugs: application, process, and trial. Journal of nuclear medicine technology. 1990 Dec 1;18(4):236-42.
13. Chiodin D, Cox EM, Edmund AV, Kratz E, Lockwood SH. Regulatory affairs 101: introduction to investigational new drug applications and clinical trial applications. Clinical and translational science. 2019 Jul;12(4):334-42.
14. Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. JACC: Basic to Translational Science. 2016 Apr;1(3):170-9.
15. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health policy. 2011 Apr 1;100(1):4-17.
16. Fargen KM, Frei D, Fiorella D, McDougall CG, Myers PM, Hirsch JA, Mocco J. The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation?. Journal of neurointerventional surgery. 2013 Jul 1;5(4):269-75.
17. Kepplinger EE. FDA's expedited approval mechanisms for new drug products. Biotechnology law report. 2015 Feb 1;34(1):15-37.
18. View of the stages of drug discovery and development process. (n.d.). Ajprd.Com. Retrieved January 2, 2022, from https://www.ajprd.com/index.php/journal/article/view/616/510
19. Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Therapeutic advances in drug safety. 2013 Oct;4(5):211-9.
20. Raj N, Fernandes S, Charyulu NR, Dubey A, GS R, Hebbar S. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Therapeutic advances in drug safety. 2019 Jul;10:2042098619865413.
21. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. Jama. 1999 Mar 3;281(9):824-9.
22. Kleczyk E. Risk management in the development of new products in the pharmaceutical industry.
23. Azarnoff DL, Herting RL. Drug development: risks and problems. Annals of the New York Academy of Sciences. 1984 Dec;432(1):279-86.
24. Kannt A, Wieland T. Managing risks in drug discovery: reproducibility of published findings. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016 Apr;389:353-60.
25. Risk management - FDA’s Quality Risk Management approach to new drug applications. (2019, April 1). Drug Development and Delivery. https://drug-dev.com/fdas-quality-risk-management-approach-to-new-drug-applications/
26. Yildirim O, Gottwald M, Schüler P, Michel MC. Opportunities and challenges for drug development: public–private partnerships, adaptive designs and big data. Frontiers in pharmacology. 2016 Dec 6;7:461.
27. Surur AS, Fekadu A, Makonnen E, Hailu A. Challenges and opportunities for drug discovery in developing countries: the example of cutaneous leishmaniasis. ACS Medicinal Chemistry Letters. 2020 Sep 2;11(11):2058-62.
28. Norris SM, Palmer C, Stroud C, Altevogt BM. Forum on Neuroscience and Nervous System Disorders, Board on Health Science Policy, Institute of Medicine. InDeveloping a 21st Century Neuroscience: Workshop Summary 2015.

© STM Journals 2024. All Rights Reserved